glycomics
Just months after launching a test for guiding immunotherapy, the glycoproteomics firm has switched priorities to a colorectal cancer screening assay.
InterVenn Biosciences Raises $34M in Series B Round to Commercialize Ovarian Cancer Test
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
Iceni Diagnostics Developing Point-of-Care, Lateral Flow Assay for SARS-CoV-2
Iceni Diagnostics aims to deliver a rapid, point-of-care test that could differentiate the virus from more common flu strains using artificial glycan receptors.
Launched to commercialize technologies from two leading glycoproteomic researchers, the startup's lead test is a mass spec-based assay for triaging pelvic masses.
InterVenn BioSciences Raises $9.4M in Funding
The company plans to use the funds to develop and commercialize its lead product, a mass spectrometry-based glycoproteomic blood test for ovarian cancer.